These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21626075)

  • 1. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B.
    Tsuboi H; Tsujii A; Nampei A; Yoshihara H; Kawano K; Takeuchi E; Shi K
    Mod Rheumatol; 2011 Dec; 21(6):701-5. PubMed ID: 21626075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of bilateral rheumatoid pleuritis successfully treated with tocilizumab.
    Ohtsuka K; Takeuchi K; Matsushita M; Aramaki T
    Mod Rheumatol; 2014 Nov; 24(6):1001-4. PubMed ID: 24533552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis.
    Mori S
    Mod Rheumatol; 2012 Nov; 22(6):947-50. PubMed ID: 22350573
    [No Abstract]   [Full Text] [Related]  

  • 4. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
    Yokoe I; Nishio S; Sato H; Kobayashi H
    Mod Rheumatol; 2011 Dec; 21(6):710-4. PubMed ID: 21656090
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B.
    Doubrawa E; Ricca RA; Malucelli TO; Pizzol VI; Barros DH; Paiva ES
    Rev Bras Reumatol; 2012 Aug; 52(4):653-5. PubMed ID: 22885430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
    Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
    Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus.
    Zhang X; Zhang F; Wu D; Bao C; Zhu P; Zhang X; Huang C; He D; Tao Y; Fang Y; Gu J; Wu H; Sun L; Yang X; Huang F; Xu H; Zhao D; Zhang M; Zheng Y; Li Z
    Int J Rheum Dis; 2013 Aug; 16(4):408-12. PubMed ID: 23992260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.
    Benucci M; Manfredi M; Mecocci L
    J Clin Rheumatol; 2008 Aug; 14(4):245-6. PubMed ID: 18766129
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab.
    Honda H; Kida H; Yoshida M; Tomita T; Fujii M; Ihara S; Goya S; Tachibana I; Kawase I
    Mod Rheumatol; 2011 Dec; 21(6):660-4. PubMed ID: 21472474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital.
    Golmia RP; Scheinberg MA
    Einstein (Sao Paulo); 2013 Dec; 11(4):492-4. PubMed ID: 24488390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 18. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment.
    Thonhofer R; Gaugg M; Kriessmayr M; Neumann HJ; Erlacher L
    Ann Rheum Dis; 2005 Jul; 64(7):1098-9. PubMed ID: 15958773
    [No Abstract]   [Full Text] [Related]  

  • 20. [Case of miliary tuberculosis during treatment with infliximab for rheumatoid arthritis].
    Taniguchi H; Izumi S
    Kekkaku; 2008 May; 83(5):431-4. PubMed ID: 18536334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.